Blue Trust’s Adaptive Biotechnologies ADPT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$319 Buy
+11
New +$270 ﹤0.01% 2327
2025
Q3
– Sell
-21
Closed -$245 – 2566
2025
Q2
$245 Buy
+21
New +$191 ﹤0.01% 2370
2024
Q4
– Sell
-91
Closed -$329 – 2431
2024
Q3
$329 Buy
+91
New +$396 ﹤0.01% 2829
2024
Q1
– Sell
-364
Closed -$2K – 2161
2023
Q4
$2K Buy
+364
New +$1.66K ﹤0.01% 2084
2023
Q1
– Sell
-55
Closed – – 2271
2022
Q4
$0 Hold
55
– – ﹤0.01% 2195
2022
Q3
$0 Buy
+55
New +$518 ﹤0.01% 2059

Other funds holding ADPT

Blue Trust's ADPT Position: Q3 2026 in Review

Blue Trust opened a new position in Adaptive Biotechnologies (ADPT) in Q3 2026: 11 shares worth $319. The stake represents ﹤0.01% of the portfolio and ranks #2327 among its holdings. This is a return to the name: Blue Trust previously reported a position in ADPT as recently as Q2 2025.

Blue Trust first reported a position in ADPT in Q3 2022 and has held it in 6 quarters since. The position peaked at $2K in Q4 2023. 252 funds tracked by Wall St. Rank hold ADPT as of Q3 2026.

  • Blue Trust held 11 shares of Adaptive Biotechnologies worth $319 as of Q3 2026.
  • Adaptive Biotechnologies was a new Blue Trust position in Q3 2026.
  • Adaptive Biotechnologies made up ﹤0.01% of Blue Trust's portfolio in Q3 2026, its #2327 holding.
  • Blue Trust first reported a position in Adaptive Biotechnologies in Q3 2022 and has held it in 6 quarters since.
  • Blue Trust's Adaptive Biotechnologies position peaked at $2K in Q4 2023.
  • 252 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q3 2026.

Based on Blue Trust's 13F filing for Q3 2026, filed 15 Oct 2026.